Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Kim

Showing results (341-350 of 529) with videos related to

Pageof 53
Sort By:
Bone Marrow Transplantation|August 3, 2004
Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in KoreaJ-H Yoo, D-G Lee, S M Choi, et al.
Bone Marrow Transplantation|June 6, 2006
Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantationC-K Min, S Y Kim, M J Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.
Bone Marrow Transplantation|October 9, 2007
Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemiaH-J Kim, W-S Min, K-S Eom, et al.
Leukemia|October 1, 2010
Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemiaS Lee, N-G Chung, B-S Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2009
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinomaY Koh, T M Kim, Y K Jeon, et al.
Letters in Applied Microbiology|January 11, 2007
Toluene-induced accumulation of trehalose by Pseudomonas sp. BCNU 106 through the expression of otsA and otsB homologuesH C Park, Y U Bae, S D Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2026
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399]H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.
Pageof 53

Showing results (341-350 of 529) with videos related to

Sort By:
Pageof 53
Bone Marrow Transplantation|August 3, 2004
Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in KoreaJ-H Yoo, D-G Lee, S M Choi, et al.
Bone Marrow Transplantation|June 6, 2006
Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantationC-K Min, S Y Kim, M J Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2021
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 studyD S-W Tan, M Thomas, D-W Kim, et al.
Bone Marrow Transplantation|October 9, 2007
Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemiaH-J Kim, W-S Min, K-S Eom, et al.
Leukemia|October 1, 2010
Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemiaS Lee, N-G Chung, B-S Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2009
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinomaY Koh, T M Kim, Y K Jeon, et al.
Letters in Applied Microbiology|January 11, 2007
Toluene-induced accumulation of trehalose by Pseudomonas sp. BCNU 106 through the expression of otsA and otsB homologuesH C Park, Y U Bae, S D Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyT Mok, D R Camidge, S M Gadgeel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2026
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399]H S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN studyA T Shaw, B J Solomon, E Felip, et al.
Pageof 53